Anna von Rossum

Anna von Rossum is a Senior Scientist specializing in Multispecific Antibody Therapeutics at Zymeworks Inc., where responsibilities include advancing antibody therapeutics with a focus on multispecifics, cell-engagers, and checkpoint inhibitors since March 2019. Prior experience includes an Associate Scientist role at The Centre for Drug Research & Development, where Anna led immunological assays in various collaborations, and a Post-Doctoral Fellowship in Immunotherapy, contributing to CAR-based immunotherapies and intellectual property development. Anna earned a PhD in Transplant Immunology from Simon Fraser University, studying T cell death in solid organ transplantation, and holds a Bachelor's Degree in Microbiology and Immunology from the University of Victoria. Additional education includes completion of the HMX Pro Pharmacology program at Harvard Medical School.